CeriBell (NASDAQ:CBLL) Coverage Initiated by Analysts at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH assumed coverage on shares of CeriBell (NASDAQ:CBLL) in a research note issued to investors on Friday, Marketbeat.com reports. The firm issued a buy rating and a $32.00 target price on the stock.

CBLL has been the topic of a number of other reports. TD Cowen raised their price target on CeriBell from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Canaccord Genuity Group reissued a “buy” rating and set a $33.00 target price on shares of CeriBell in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, CeriBell has an average rating of “Buy” and a consensus target price of $32.50.

CeriBell Price Performance

Shares of CeriBell stock opened at $18.44 on Friday. The stock’s 50-day moving average is $21.95. CeriBell has a one year low of $17.67 and a one year high of $32.75.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million for the quarter, compared to the consensus estimate of $17.55 million. On average, sell-side analysts predict that CeriBell will post -2.46 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Legal & General Group Plc purchased a new position in CeriBell during the 4th quarter worth $32,000. Summit Investment Advisors Inc. purchased a new position in CeriBell during the 4th quarter worth $33,000. Tower Research Capital LLC TRC acquired a new stake in shares of CeriBell in the 4th quarter worth $37,000. BNP Paribas Financial Markets acquired a new position in shares of CeriBell during the fourth quarter worth about $43,000. Finally, PNC Financial Services Group Inc. purchased a new position in CeriBell during the fourth quarter worth about $47,000.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.